Skip to main content
SpringerLink
Log in

Imatinib: As Adjuvant Therapy for Gastrointestinal Stromal Tumor

Profile Report

  • Adis Profile Report
  • Published:
BioDrugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

References

  1. DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231 (1): 51–8

    Article  PubMed  CAS  Google Scholar 

  2. Blackstein ME, Blay J-Y, Corless C, et al. Gastrointestinal stromal tumours: consensus statement on diagnosis and treatment. Can J Gastroenterol 2006 Mar; 20 (3): 157–63

    PubMed  Google Scholar 

  3. Siddiqui MA, Scott LJ. Imatinib: a review of its use in the management of gastrointestinal stromal tumours. Drugs 2007; 67 (5): 805–20

    Article  PubMed  CAS  Google Scholar 

  4. Rubin BP, Singer S, Tsao C, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001 Nov 15; 61 (22): 8118–21

    PubMed  CAS  Google Scholar 

  5. Goettsch WG, Bos SD, Breekveldt-Postma N, et al. Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study. Eur J Cancer 2005 Dec; 41 (18): 2868–72

    Article  PubMed  Google Scholar 

  6. vanOosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001 Oct 27; 358 (9291): 1421–3

    Article  PubMed  Google Scholar 

  7. Demetri GD, vonMehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002 Aug 15; 347 (7): 472–80

    Article  PubMed  CAS  Google Scholar 

  8. Verweij J, vanOosterom A, Blay JY, et al. Imatinib mesylate (STI-571 Glivec®, Gleevec™) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target: results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 2003 Sep; 39 (14): 2006–11

    Article  PubMed  CAS  Google Scholar 

  9. Novartis. Gleevec® (imatinib mesylate tablets): US prescribing information [online]. Available from URL: http://www.pharma.us.novartis.com/product/pi/pdf/gleevec_tabs.pdf[Accessed 2010 Aug 18]

  10. European Medicines Agency. Glivec®: summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/humandocs/PDFs/EPAR/glivec/emea-combined-h406en.pdf[Accessed 2010 Aug 18]

  11. Heinrich MC, Griffith DJ, Druker BJ, et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000; 96 (3): 925–32

    PubMed  CAS  Google Scholar 

  12. Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor ST1571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295 (1): 139–45

    PubMed  CAS  Google Scholar 

  13. Sleijfer S, Wiemer E, Seynaeve C, et al. Improved insight into resistance mechanisms to imatinib in gastrointestinal stromal tumors: a basis for novel approaches and individualization of treatment. Oncologist 2007 Jun; 12 (6): 719–26

    Article  PubMed  CAS  Google Scholar 

  14. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003 Dec 1; 21 (23): 4342–9

    Article  PubMed  CAS  Google Scholar 

  15. Sanford M, Scott LJ. Imatinib: as adjunctive therapy for gastrointestinal stromal tumour. Drugs 2010; 70 (15): 1963–72

    Article  PubMed  CAS  Google Scholar 

  16. Debiec-Rychter M, Dumez H, Judson I, et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2004 Mar; 40 (5): 689–95

    Article  PubMed  CAS  Google Scholar 

  17. Debiec-Rychter M, Sciot R, Le Cesne A, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006 May; 42 (8): 1093–103

    Article  PubMed  CAS  Google Scholar 

  18. DeMatteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009 Mar 28; 373 (9669): 1097–104

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments and Disclosures

The original article[15] was reviewed by: N. Boku, Division of Gastrointestinal Oncology, Shizuoka Cancer Centre, Shizuoka, Japan; S. Kadkol, Department of Pathology, University of Illinois at Chicago, Chicago, Illinois, USA; T. Takahata, Department of Medical Oncology, Graduate School of Medicine, Hirosaki University, Hirosaki, Japan.

The manufacturer of the agent under review was offered an opportunity to comment on the original article[15] during the peer review process; changes based on any comments received were made on the basis of scientific and editorial merit. The preparation of the original article and the profile report was not supported by external funding.

Author information

Authors and Affiliations

  1. Adis, a Wolters Kluwer Business, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, Auckland, 0754, New Zealand

    Mark Sanford & Lesley J. Scott

Authors
  1. Mark Sanford
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lesley J. Scott
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark Sanford.

Additional information

Adapted and reproduced from the original article published in Drugs 2010; 70 (15): 1963–72

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sanford, M., Scott, L.J. Imatinib: As Adjuvant Therapy for Gastrointestinal Stromal Tumor. BioDrugs 25, 191–192 (2011). https://doi.org/10.2165/11207040-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11207040-000000000-00000

Keywords

Search

Navigation